New cocktail aims to tackle rare lymphoma without chemo
NCT ID NCT07299331
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs—zanubrutinib, rituximab, and lenalidomide—as the first treatment for people with marginal zone lymphoma that has spread or requires therapy. Researchers want to see if this drug mix helps tumors shrink or disappear and how safe it is. Fifty adults aged 18 to 75 will take the drugs and visit the clinic regularly for checkups and tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib, rituximab, and lenalidomide
What this could lead to
If successful, this combination could offer a more effective first-line treatment for marginal zone lymphoma, potentially improving remission rates and delaying disease progression.
What could go wrong
This is an early, single-arm study with only 50 participants, so results may not apply broadly. The drug combination can cause side effects like low blood counts and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.